Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday. The post Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations appeared first on Investor's Business Daily.
Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.
The post Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
